Olr775 inhibitors are a specialized class of chemical compounds that function by modulating the activity of the olfactory receptor 775 (Olr775), a member of the G-protein-coupled receptor (GPCR) family. Olr775 is part of a vast array of olfactory receptors responsible for detecting a diverse range of odorants in the environment, contributing to the sense of smell. These receptors, located on the olfactory epithelium in the nasal cavity, interact with odor molecules, initiating a signal transduction cascade that results in the perception of different smells. The inhibitors of Olr775 play a crucial role in modulating these sensory inputs by selectively binding to this receptor and altering its activity. This interaction can lead to changes in the receptor's conformation and signaling pathways, thereby affecting the overall olfactory response.
Chemically, Olr775 inhibitors exhibit a variety of structural motifs, reflecting the diversity of the ligands that can bind to olfactory receptors. These inhibitors are designed to fit into the binding pocket of Olr775, often utilizing hydrogen bonding, hydrophobic interactions, and Van der Waals forces to achieve high affinity and specificity. The structural design of these inhibitors can include a range of functional groups and molecular frameworks, such as heterocyclic rings, aromatic moieties, and aliphatic chains, which contribute to their binding properties. The study and development of Olr775 inhibitors involve extensive use of techniques such as X-ray crystallography, molecular docking, and computational modeling to understand the receptor-ligand interactions at a molecular level. This understanding helps in refining the inhibitors' design to enhance their efficacy and specificity, providing valuable insights into the intricate mechanisms of olfactory signaling and receptor modulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Targets BCR-ABL kinase, possibly affecting related signaling pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Multi-kinase inhibitor, potentially influencing RAF/MEK/ERK signaling. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
BRAF inhibitor, potentially impacting the MAPK/ERK pathway. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Receptor tyrosine kinase inhibitor, potentially affecting angiogenesis pathways. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK1/2 inhibitor, possibly influencing cytokine signaling pathways. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
BCL-2 inhibitor, potentially affecting apoptosis pathways. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
EGFR inhibitor, potentially affecting epidermal growth factor receptor signaling. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
mTOR inhibitor, potentially influencing cell growth and proliferation. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Bruton's tyrosine kinase inhibitor, possibly affecting B-cell receptor signaling. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
MEK inhibitor, potentially impacting the MAPK/ERK pathway. | ||||||